Large Markets with Distinct National Rules

Part of Regulatory Affairs and the Jurisdiction Map: Jurisdictions with Their Own Instruments.

About 5 minutes. Free, in your language, no account needed.

Why this matters

A group of large, strategically important markets participate in international harmonization while maintaining national requirements that are substantial, specific, and frequently decisive for whether a trial can run there at all.

These are not minor variations. They include requirements for local data, local sponsor presence, and in some cases restrictions on which trials may be conducted. A sponsor that treats these countries as standard ICH jurisdictions will plan a timeline that cannot be met.

India

India is recorded in CRLN's register as an ICH Observer. Its governing instrument is the New Drugs and Clinical Trials Rules, 2019, First Schedule, setting out general principles and practices for clinical trials, which superseded the earlier Schedule Y. The authority is the Central Drugs Standard Control Organisation, with the Drugs Controller General of India. CDSCO is benchmarked at WHO maturity level 3 for vaccines as a producing country, first benchmarked in 2017 and reassessed in 2024.

The 2019 Rules were a substantial reform, introducing defined timelines for review, provisions on compensation for trial-related injury, and requirements around ethics committee registration. The compensation provisions in particular are more prescriptive than most jurisdictions and require specific attention at protocol and budget stage rather than at the point of an injury.

A team working from pre-2019 material is working from a superseded framework, which is the single most likely error in Indian regulatory work.

China

China is recorded as an ICH member jurisdiction, with the National Medical Products Administration as its authority, benchmarked at WHO maturity level 3.

China's accession to international harmonization drove significant reform, and the framework has moved substantially. The features that persist and matter operationally are requirements relating to human genetic resources, which govern the collection, storage and export of biological samples and associated data, and which are administered separately from the trial authorization. A study collecting samples for analysis outside the country engages a distinct approval process that runs on its own timeline.

Sample export is the specific thing to establish early, because it is frequently on the critical path and is frequently discovered late.

South Korea

South Korea is an ICH member jurisdiction. Its authority, the Ministry of Food and Drug Safety, is benchmarked at WHO maturity level 4, the advanced designation. South Korea is a high capability regulatory environment and a common early inclusion in Asian trial programs for that reason.

Singapore

Singapore is an ICH member jurisdiction with the Health Sciences Authority benchmarked at WHO maturity level 4. Like South Korea, it combines high regulatory capability with predictable timelines, and it is frequently used as a regional hub.

Note what maturity level 4 does and does not tell you here. It describes the regulatory system's performance. It does not tell you the review will be fast for your particular application, and it does not remove any national requirement.

Türkiye and Brazil

Türkiye is an ICH member jurisdiction with the Turkish Medicines and Medical Devices Agency benchmarked at WHO maturity level 3. Brazil is recorded as an ICH member jurisdiction. Both are substantial markets with their own national requirements around local representation and documentation, and both reward early engagement over a late standard submission.

In practice

A sponsor designs a study with central laboratory analysis of blood samples, with all samples shipped to a single facility.

In most participating countries this is routine. In China it engages the human genetic resources framework, which requires its own approval for the collection and export of samples, administered separately from the trial authorization and on its own timeline.

The regulatory lead identifies this at protocol design stage and puts two options to the study team: pursue the separate approval, accepting the additional lead time, or analyze Chinese samples locally and accept the cross-site comparability question that creates.

Either answer is workable. What is not workable is discovering the requirement after the trial is authorized and the samples are sitting in a freezer, which is where this is usually discovered.

What this looks like when it goes wrong

A team prepares an Indian submission using a template built from a study conducted in 2017, under Schedule Y.

Schedule Y was superseded by the 2019 Rules. The template's compensation provisions, its ethics committee expectations and its timeline assumptions all reflect a framework that no longer governs.

The submission is not rejected outright, which would be simpler. It attracts a long series of questions, each of which reveals another place where the template reflects the old framework, and the sponsor spends four months converging on a submission it could have made correctly at the start.

The template looked current because it had been used successfully. It had been used successfully before the framework changed.

Key takeaways